Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (OTCQX: RHHBY) inaugurated a new research home for the Institute of Human Biology on 23 March 2026, part of a CHF 1.4 billion site investment in Basel & Kaiseraugst.
Building 92 houses up to 250 researchers, focuses on human organoids, organ-on-chip and AI-driven in silico models, and reinforces Roche's multi-year Swiss R&D investments totaling around CHF 41 billion (2016–2025).
Roche (OTCQX: RHHBY) announced on March 18, 2026 that the FDA has classified its Ionify steroid assays as CLIA "moderate complexity," expanding routine clinical access to mass spectrometry testing. The assays (Estradiol, DHEA, DHEA-S, Progesterone, 17-Hydroxyprogesterone, Androstenedione) run on the cobas i 601 analyzer.
The designation follows Roche's earlier Ionify 25-Hydroxy Vitamin D Total approval and aims to standardize and automate mass spec workflows, reducing lab variability and enabling wider clinical adoption while Roche continues regulatory review of additional assays.
Roche (OTCQX: RHHBY) launched a large-scale hybrid-cloud NVIDIA AI factory on 16 March 2026, adding 2,176 Blackwell GPUs to reach a total exceeding 3,500 GPUs across on-premise and cloud infrastructure.
The platform embeds AI across R&D, manufacturing, diagnostics and digital health, supporting Lab-in-the-Loop, digital twins, accelerated genomic and pathology analysis, and conversational healthcare AI to speed drug and diagnostic development.
Roche (RHHBY) received CE mark on March 16, 2026 for the Elecsys ApoE4 blood-based IVD immunoassay, the first CE-marked test to identify ApoE4 carriers from a simple blood sample. The test screens carriers vs non-carriers, reducing the need for broad DNA testing and supporting DMT decisions.
The assay integrates with existing Roche instruments in CE-mark countries, offering a scalable plasma-based solution to triage patients with cognitive decline.
Roche (OTCQX: RHHBY) shareholders approved all Board proposals at the 10 March 2026 Annual General Meeting. Key outcomes: re-election of Severin Schwan as Chairman, 39th consecutive dividend increase to CHF 9.80 per share, approval to exchange Genussscheine for Participation Certificates (ticker ROP), and reduction of nominal share value to CHF 0.001.
Shareholders representing 77.22% of shares attended; key votes passed with high majorities, and KPMG AG was appointed statutory auditor for 2026.
Genentech (OTCQX: RHHBY) announced Phase III persevERA results in ER-positive, HER2-negative advanced breast cancer on March 9, 2026. The study did not meet its primary endpoint of a statistically significant progression-free survival benefit for giredestrant plus palbociclib versus letrozole plus palbociclib, though a numerical improvement was observed.
Adverse events were manageable and consistent with known safety profiles. Genentech cites positive evERA and lidERA readouts, FDA acceptance of an NDA based on evERA, and plans to submit lidERA data to the FDA in the coming weeks.
Roche (OTCQX: RHHBY) reported that the phase III persevERA study of giredestrant plus palbociclib in 1L ER+/HER2- advanced breast cancer did not meet its primary endpoint of a statistically significant improvement in progression-free survival, though a numerical improvement was observed.
Safety was manageable and consistent with known profiles. The FDA accepted a giredestrant NDA based on evERA data; lidERA phase III data will be submitted to the FDA in the coming weeks. Full persevERA results will be presented at a medical meeting; pionERA is expected to read out in 2027.
Genentech (OTCQX: RHHBY) reported Phase III ALLEGORY results showing Gazyva plus standard therapy met the primary endpoint in systemic lupus erythematosus (SLE).
At 52 weeks, 76.7% of Gazyva patients achieved SRI-4 versus 53.5% with placebo (adjusted difference 23.1%, 95% CI: 12.5–33.6; p<0.001). All five key secondary endpoints were met and safety aligned with the known profile.
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly reduced SLE disease activity at 52 weeks. Primary SRI-4 response was 76.7% vs 53.5% (adjusted difference 23.1%, 95% CI 12.5–33.6; p<0.001).
All five key secondary endpoints were met, including BICLA, sustained glucocorticoid reduction to ≤7.5 mg/day, SRI-6, longer time to first BILAG flare (HR 0.58, p=0.002) and higher DORIS remission (35.1% vs 13.8%). Safety was consistent with the known profile.
Roche (OTCQX: RHHBY) reported positive Phase II ZUPREME-1 topline results for petrelintide, an investigational once-weekly amylin analog for chronic weight management. In 493 participants (mean BMI 37 kg/m2), petrelintide produced up to 10.7% mean body weight loss at week 42 versus 1.7% with placebo (p<0.001) and showed placebo-like tolerability.
The maximally effective dose had no vomiting and no discontinuations for GI adverse events; 98% reached maintenance dose. Roche plans further development, ZUPREME-2 topline in H2 2026, and a combination trial in 2026.